Predictors of severe COVID-19: older age and comorbidity
- Authors: Konnov V.V.1,2, Tsygankova A.E.1,2, Gerasimov A.N.3, Timonina K.A.2, Tsvetkova N.A.1, Potekaeva S.A.1, Umbetova K.T.2, Volchkova E.V.2
-
Affiliations:
- Infectious Clinical Hospital No 2, Moscow
- Sechenov First Moscow State Medical University
- Centre for Strategic Planning and Management of Biomedical Health Risks
- Issue: Vol 30, No 3 (2025)
- Pages: 180-193
- Section: Original study articles
- URL: https://ogarev-online.ru/1560-9529/article/view/373791
- DOI: https://doi.org/10.17816/EID688872
- EDN: https://elibrary.ru/SQADTK
- ID: 373791
Cite item
Abstract
BACKGROUND: Older age and comorbidity are recognized as significant risk factors for severe COVID-19. However, the combined impact of these factors on disease outcomes, especially in different age groups, remains unclear. This study focuses on older patients with chronic comorbidities in order to address this gap.
AIM: This study aimed to evaluate the role of older age and comorbidities in prediction of severe COVID-19 and mortality in hospitalized patients.
METHODS: This cross-sectional, retrospective study included 604 patients aged 18–99 years who were treated at Infectious Diseases Clinical Hospital No. 2 of the Moscow Healthcare Department for laboratory-confirmed (ICD-10 code: U07.1) COVID-19 between September 2020 and November 2022. Demographic characteristics, comorbidities, clinical outcomes (recovery, improvement, and mortality rates), and COVID-19 severity were evaluated.
RESULTS: An analysis of 604 hospitalized patients revealed an increase in mortality rates with age: 4.1% in patients under 60 years old, 12.7% in patients aged 60–74 years, 16.4% in patients aged 75–89 years, and 21.9% in patients aged 90 years and older. The most common comorbidity-associated risk factors included chronic kidney disease (mortality rate: 23.2%), myocardial ischemia (19.7%), and type 2 diabetes mellitus (18%). The infection was atypical, without fever in 21% of patients, primarily those in the older age group. Stratified analysis showed that the role of specific risk factors, such as chemotherapy, myocardial ischemia, and chronic kidney disease, varied across age groups.
CONCLUSION: Older age and comorbidities are independent risk factors for severe COVID-19 and fatal outcomes. Patients over the age of 75 years with chronic diseases require special attention. Early diagnosis and personalized management strategies may improve outcomes in this age group.
About the authors
Vladislav V. Konnov
Infectious Clinical Hospital No 2, Moscow; Sechenov First Moscow State Medical University
Email: konnov.vlad@gmail.com
ORCID iD: 0000-0002-4978-4139
SPIN-code: 6228-2241
MD
Russian Federation, Moscow; MoscowAnna E. Tsygankova
Infectious Clinical Hospital No 2, Moscow; Sechenov First Moscow State Medical University
Author for correspondence.
Email: anna.tsygankova.inf@gmail.com
ORCID iD: 0000-0003-3766-1868
SPIN-code: 6583-0476
MD, Cand. Sci. (Medicine);
Russian Federation, Moscow; MoscowAndrey N. Gerasimov
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: andr-gerasim@yandex.ru
ORCID iD: 0000-0003-4549-7172
SPIN-code: 4742-1459
Dr. Sci. (Physics and Mathematics), Assistant Professor
Russian Federation, MoscowKsenia A. Timonina
Sechenov First Moscow State Medical University
Email: ksuchatimonina@gmail.com
ORCID iD: 0009-0005-9764-8106
Russian Federation, Moscow
Natalia A. Tsvetkova
Infectious Clinical Hospital No 2, Moscow
Email: 3655192@mail.ru
ORCID iD: 0000-0003-3323-3401
SPIN-code: 5322-6167
MD, Cand. Sci. (Medicine);
Russian Federation, MoscowSvetlana A. Potekaeva
Infectious Clinical Hospital No 2, Moscow
Email: infection_mma@mail.ru
ORCID iD: 0000-0002-4771-9616
SPIN-code: 6105-8492
MD, Dr. Sci. (Medicine)
Russian Federation, MoscowKarina T. Umbetova
Sechenov First Moscow State Medical University
Email: karinasara@inbox.ru
ORCID iD: 0000-0003-0902-9267
SPIN-code: 3197-9205
MD, Dr. Sci. (Medicine), Professor
Russian Federation, MoscowElena V. Volchkova
Sechenov First Moscow State Medical University
Email: antononina@rambler.ru
ORCID iD: 0000-0003-4581-4510
SPIN-code: 3342-4681
MD, Dr. Sci (Medicine), Professor
Russian Federation, MoscowReferences
- Samadizadeh S, Masoudi M, Rastegar M, et al. COVID-19: Why does disease severity vary among individuals? Respir Med. 2021;180:106356. doi: 10.1016/j.rmed.2021.106356 EDN: MGJJJQ
- Morani I, Shibli H, Karasik D, Edelstein M. Determining population-specific risk factors for COVID-19 susceptibility and severity to inform future individual-level integrated risk scoring. BMC Infect Dis. 2025;25(1):977. doi: 10.1186/s12879-025-11357-9
- Satué-Gracia EM, Vila-Córcoles A, de Diego-Cabanes C, et al. Susceptibility and risk of SARS-CoV-2 infection among middle-aged and older adults in Tarragona area, Spain. Med Clin (Barc). 2022;158(6):251–259. doi: 10.1016/j.medcli.2021.03.027 EDN: PRPXFS
- Radygina LV, Mochalova LV. Factors affecting the severity of COVID-19 and the development of complications. Microbiology Independent Research Journal (MIR Journal). 2023;10(1):20–38. doi: 10.18527/2500-2236-2023-10-1-20-38.RU EDN: AHCRUR
- Tsygankova AE, Gerasimov AN, Chulanov VP, et al. Previously diagnosed HIV infection in patients with COVID-19 and advanced HIV disease improves their survival. Arch Clin Infect Dis. 2023;18(5):e142231. doi: 10.5812/archcid-142231 EDN: PQVNXN
- Tkacheva ON, Kotovskaya YuV, Aleksanyan LA, et al. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020;19(3):2601. doi: 10.15829/1728-8800-2020-2601 EDN: LONZLO
- Farshbafnadi M, Kamali Zonouzi S, Sabahi M, et al. Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors. Exp Gerontol. 2021;154:111507. doi: 10.1016/j.exger.2021.111507 EDN: VGHNTU
- Avdeev SN, Gaynitdinova VV, Pozdniakova AA, et al. Risk factors for adverse outcomes in elderly patients with asthma and severe COVID-19 at the hospital and early post-hospital stages. Terapevticheskii Arkhiv. 2023;95(1):57–65. doi: 10.26442/00403660.2023.01.202049 EDN: GPLACG
- Schultz MJ, van Oosten PJ, Hol L. Mortality among elderly patients with COVID-19 ARDS — age still does matter. Pulmonol. 2023;29(5):353–355. doi: 10.1016/j.pulmoe.2023.02.013 EDN: ZHVXVI
- Sharipova MM, Ivkina MV, Arkhangelskaia AN, et al. Features of the course of COVID-19 in patients with comorbid pathology. Meditsinskiy sovet = Medical Council. 2022;(6):44–49. doi: 10.21518/2079-701X-2022-16-6-44-49 EDN: RSITDA
- Warren-Gash C, Davidson JA, Strongman H, et al. Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study. Lancet Reg Health Eur. 2023;27:100604. doi: 10.1016/j.lanepe.2023.100604 EDN: AOHLZQ
- Hall EJ, Ayers CR, Kolkailah AA, et al. Longitudinal trends in cardiovascular risk factor profiles and complications among patients hospitalized for COVID-19 infection: results from the american heart association COVID-19 cardiovascular disease registry. Circ Cardiovasc Qual Outcomes. 2023;16(5):e009652. doi: 10.1161/CIRCOUTCOMES.122.009652 EDN: ZLOJWZ
- Mokrysheva NG, Shestakova MV, Vikulova OK, et al. Analysis of risk factors for COVID-19-related fatal outcome in 337991 patients with type 1 and type 2 diabetes mellitus in 2020–2022 years: Russian nationwide retrospective study. Diabetes Mellitus. 2022;25(5):404–417. doi: 10.14341/DM12954 EDN: TYFVHG
- Al-Azzam N, Al-Azzam S, Khassawneh B, et al. Factors contributing to poor COVID-19 outcomes in diabetic patients: Findings from a single-center cohort study. PLoS One. 2023;18(8):e0290946. doi: 10.1371/journal.pone.0290946 EDN: YLPCYJ
- Mara G, Nini G, Cotoraci C. Chronic obstructive pulmonary disease and COVID-19: The impact of hematological biomarkers on disease severity and outcomes. J Clin Med. 2025;14(8):2765. doi: 10.3390/jcm14082765
- Avdeev SN, Adamyan LV, Alexeeva EI, et al. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Versions 1–17 [Internet] [cited 2025 Nov 25]. (In Russ.) Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/064/610/original/%D0%92%D0%9C%D0%A0_COVID-19_V18.pdf EDN: PDXQNY
- Age-friendly environments in Europe: Indicators, monitoring and assessments. Copenhagen: World Health Organization Regional Office for Europe; 2018 [cited 2025 Aug 7]. ISBN: 978-9-2890-5777-6 Available from: https://www.who.int/europe/ru/publications/i/item/WHO-EURO-2018-1088-40834-55192
- Wang A, Li K, Sun H, et al. Assessing the impact of comorbidities on disease severity in COVID-19 patients requires consideration of age. Medicine. 2025;104(5):e41360. doi: 10.1097/md.0000000000041360 EDN: NOUPZP
- Ge E, Li Y, Wu S, et al. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS One. 2021;16(10):e0258154. doi: 10.1371/journal.pone.0258154 EDN: DLVCYI
- Patrascu R, Dumitru CS, Laza R, et al. The role of age and comorbidity interactions in COVID-19 mortality: insights from cardiac and pulmonary conditions. J Clin Med. 2024;13(24):7510. doi: 10.3390/jcm13247510 EDN: FSZPEN
- Cai R, Zhang J, Zhu Y, et al. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. Int Urol Nephrol. 2021;53(8):1623–1629. doi: 10.1007/s11255-020-02740-3 EDN: FTUWOP
- Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes. 2021;11(1):21. doi: 10.1038/s41387-021-00163-2 EDN: MCMYUO
- Jani CT, Schooley RT, Mckay RR, Lippman SM. Cancer, more than a “COVID-19 co-morbidity”. Front Oncol. 2023;13:1107384. doi: 10.3389/fonc.2023.1107384
- Abul Y, Leeder C, Gravenstein S. Epidemiology and clinical presentation of COVID-19 in older adults. Infect Dis Clin North Am. 2023;37(1):1–26. doi: 10.1016/j.idc.2022.11.001 EDN: KBYPMZ
- Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023;11(5):453–464. doi: 10.1016/S2213-2600(22)00528-8 EDN: GSIBDQ
Supplementary files

